42 results
6-K
EX-99.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
10 Apr 24
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
8:50am
to certain side effects in current standard care solutions that use antiseptic agents and materials, such as allergies. These standard care solutions may
424B5
IINN
Inspira Technologies Oxy B.H.N. Ltd
1 Apr 24
Prospectus supplement for primary offering
4:01pm
solely as an inactive textual reference. We will post on our website any materials required to be so posted on such website under applicable corporate
6-K
EX-10.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
1 Apr 24
Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO’s Mother with Leading Fund Manager
8:46am
the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including … , releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, “Hazardous Materials
6-K
EX-99.1
IINN
Inspira Technologies Oxy B.H.N. Ltd
12 Mar 24
Inspira™ Releases New Data Demonstrating Superiority of its Core Technology, Across Key Endpoints of HMSS Indicator
4:01pm
materials will significantly reduce manufacturing costs and eliminate the global dependence on a single raw material supplier.
Inspira Technologies OXY … exchange facilitation technologies and that transitioning from fiber membrane to alternative materials will significantly reduce manufacturing costs
6-K
EX-99.1
7mkot pe1s6o47e
8 Mar 24
Notice of Extraordinary General Meeting of Shareholders
4:01pm
6-K
EX-99.1
wgpcry4 b5h0zfdy
4 Mar 24
Notice of Extraordinary General Meeting of Shareholders
4:01pm
424B5
jjtsk6cn
28 Dec 23
Prospectus supplement for primary offering
9:28am
6-K
EX-10.1
o30 9cxo9zp
27 Dec 23
Inspira Announces $3.88 Million Registered Direct Offering
4:46pm
6-K
EX-99.1
llkuyfo v5qmf1
26 Dec 23
Inspira™ Announces 95% Accuracy Results for HYLA™ Blood Sensor, Planning FDA Submission for Clearance in 2024
4:01pm
6-K
EX-99.1
e4ul6p
22 Nov 23
Notice of Annual General Meeting of Shareholders
4:01pm
POS AM
247dfx7lnz3rst5 b2t
10 Oct 23
Prospectus update (post-effective amendment)
5:00pm
6-K
EX-99.2
i25 3g8w18mk45h2
2 Oct 23
Interim Condensed Financial Statements
4:01pm
20-F/A
6dn2s2dj
19 Apr 23
Annual report (foreign) (amended)
5:42pm
6-K
EX-1.1
tw7ubjgdagj0gosx3k7n
4 Apr 23
Report of Foreign Private Issuer
4:21pm
424B5
vtsyhw0
4 Apr 23
Prospectus supplement for primary offering
4:19pm
POS AM
hvyadli 6puxbxl
13 Oct 22
Prospectus update (post-effective amendment)
4:01pm
6-K
EX-99.2
lxmpt9mgfedydfy1s0e
29 Sep 22
Interim Condensed Financial Statements
2:33pm
6-K
EX-99.1
y2sri8a7rdyyc
8 Sep 22
Notice of Annual and Extraordinary General Meeting of Shareholders
4:01pm